2022 - Research.com Best Scientist Award
2005 - Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases, American Academy of Neurology
2005 - Sedgwick Memorial Medal, American Public Health Association
2004 - Metlife Foundation Award for Medical Research in Alzheimer's Disease
His primary scientific interests are in Alzheimer's disease, Dementia, Internal medicine, Disease and Pathology. His primary area of study in Alzheimer's disease is in the field of Clinical Dementia Rating. While the research belongs to areas of Dementia, John C. Morris spends his time largely on the problem of Cognition, intersecting his research to questions surrounding Clinical psychology.
John C. Morris combines subjects such as Endocrinology and Oncology with his study of Internal medicine. In his study, which falls under the umbrella issue of Disease, Frontotemporal lobar degeneration is strongly linked to Genetics. His Cerebrospinal fluid study combines topics in areas such as Central nervous system and Amyloid.
John C. Morris mostly deals with Alzheimer's disease, Internal medicine, Disease, Dementia and Pathology. His Alzheimer's disease research is multidisciplinary, incorporating elements of Cognition, Neuroscience, Cognitive decline, Biomarker and Degenerative disease. His studies in Internal medicine integrate themes in fields like Gastroenterology, Endocrinology and Oncology.
The concepts of his Disease study are interwoven with issues in Clinical trial and Neuroimaging. A large part of his Dementia studies is devoted to Clinical Dementia Rating. John C. Morris mostly deals with Amyloid in his studies of Pathology.
His scientific interests lie mostly in Alzheimer's disease, Internal medicine, Disease, Dementia and Oncology. His study looks at the intersection of Alzheimer's disease and topics like Cognition with Cognitive decline. His Internal medicine research incorporates elements of Gastroenterology and Endocrinology.
Disease is closely attributed to Positron emission tomography in his work. His studies deal with areas such as Pittsburgh compound B, Cerebrospinal fluid, Neurodegeneration and Atrophy as well as Biomarker. As part of his studies on Pathology, he often connects relevant subjects like White matter.
His primary areas of investigation include Internal medicine, Alzheimer's disease, Disease, Dementia and Biomarker. His biological study spans a wide range of topics, including Gastroenterology and Oncology. John C. Morris is interested in Presenilin, which is a branch of Alzheimer's disease.
He works mostly in the field of Disease, limiting it down to concerns involving Immunology and, occasionally, Neurology. In Dementia, John C. Morris works on issues like Asymptomatic, which are connected to Cohort. The study incorporates disciplines such as Clinical trial, Cerebrospinal fluid, Cross-sectional study, Pittsburgh compound B and Apolipoprotein E in addition to Biomarker.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Clinical Dementia Rating (CDR): Current version and scoring rules
John C. Morris.
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann;Guy M. McKhann;David S. Knopman;Howard Chertkow;Bradley T. Hyman.
Alzheimers & Dementia (2011)
Current concepts in mild cognitive impairment.
Ronald C. Petersen;Rachelle Doody;Alexander Kurz;Richard C. Mohs.
JAMA Neurology (2001)
The consortium to establish a registry for alzheimer’s disease (CERAD). Part I. Clinical and neuropsychological assessment of alzheimer’s disease
J. C. Morris;A. Heyman;R. C. Mohs;J. P. Hughes.
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
M. Hutton;C. L. Lendon;P. Rizzu;M. Baker.
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease
Randall J. Bateman;Chengjie Xiong;Tammie L.S. Benzinger;Anne M. Fagan.
The New England Journal of Medicine (2012)
Erratum: Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease (Nature Genetics (2009) 41 (1088-1093))
D Harold;R Abraham;P Hollingworth;R Sims.
Nature Genetics (2013)
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.
Denise Harold;Richard Abraham;Paul Hollingworth;Rebecca Sims.
Nature Genetics (2009)
Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease
Joseph L. Price;John C. Morris.
Annals of Neurology (1999)
Mild cognitive impairment represents early-stage Alzheimer disease.
John C. Morris;Martha Storandt;J. Phillip Miller;Daniel W. McKeel.
JAMA Neurology (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: